DT10 Rec'd PCT/PTC 2 7 SEP 2004

FORM PTO-1390 (Modified) (REV. 07-2004) **~U.S. PATENT AND TRADEMARK OFFICE; U.S. DEPARTMENT OF COMMERCE** PG4784USw TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) U.S. APPLICATIONNO. (If known, see 37 CFR 1.5) CONCERNING A SUBMISSION UNDER 35 U.S.C. 371 TERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/EP2003/003335 27 March 2003 28 March 2002 TITLE OF INVENTION MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMMATORY DISEASES APPLICANT(S) FOR DO/EO/US R. A. Ancliff; C. M. Cook; C. D. Eldred; P. M. Gore; L. A. Harrison; M. A. Hayes; S. T. Hodgson; D. B. Judd; S. E. Keeling; X. Q. Lewell; G. Mills; G. M. Robertson; S. Swanson; A. J. Walker; M. Wilkinson Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. 2. This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), 3. (6), (9) and (24) indicated below. 4.  $\boxtimes$ The US has been elected (Article 31). 5.  $\boxtimes$ A copy of the International Application as filed (35 U.S.C. 371 (c) (2)) a. 🗆 is attached hereto (required only if not communicated by the International Bureau). b. ⊠ has been communicated by the International Bureau. is not required, as the application was filed in the United States Receiving Office (RO/US). 6. An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)). a. 🗆 is attached hereto. has been previously submitted under 35 U.S.C. 154(d)(4). 7. Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3)) П are attached hereto (required only if not communicated by the International Bureau). ъ. П have been communicated by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. d. 🛛 have not been made and will not be made. 8. An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)). An English language translation of the annexes to the International Preliminary Examination Report under PCT 10. Article 36 (35 U.S.C. 371 (c)(5)).  $\boxtimes$ 11. A copy of the International Preliminary Examination Report (PCT/IPEA/409). 12. A copy of the International Search Report (PCT/ISA/210). Items 13 to 23 below concern document(s) or information included: 13. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 14. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 15.  $\boxtimes$ A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. 16. 17. A substitute specification. 18. A power of attorney and/or change of address letter. 19. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821 - 1.825. 20. A second copy of the published International Application under 35 U.S.C. 154(d)(4). 21. A second copy of the English language translation of the International Application under 35 U.S.C. 154(d)(4).  $\boxtimes$ 22. Express Mail Label No. EV332062795US 23.  $\boxtimes$ Other items or information: Copies of: PCT publication cover page (WO 2003/082861 A3); PCT Request; 12 references listed on the enclosed form PTO-1449 as item nos. 5-14 and 16-17

## DT09 Rec'd PCT/PT0 27 SEP 2004

U.S. APPLICATION NO (if known, see 37 CFR 1.5)	i	INTERNATIONAL APPLICATION NO. PCT/EP2003/003335					ATTORNEY'S DOCKET NUMBER PG4784USW	
24. The following fees are submitted:.						CALCULATION	S PTO USE ONLY	
BASIC NATIONAL FEE (37 CFR 1.492(a)(1  Neither international preliminary examin international search fee (37 CFR 1.445(a and International Search Report not prep	ation fee (37 CFF	TO			\$1080.00			
International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO								
☐ International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO								
but international search fee (37 CFR 1.445(a)(2)) paid to USPTO								
☐ International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)								
ENTER APPROPRIATE BASIC FEE AMOUNT =						\$920.00		
Surcharge of \$130.00 for furnishing the oath or declaration later than 20 30 months from the earliest claimed priority date (37 CFR.1.492(e)).						\$0.00		
CLAIMS NUMBER FILED	NUM	NUMBER EXTRA		RATE				
Total claims 23 - 20 =		3		х	\$18.00	\$54.00		
Independent claims 3 - 3 =		0 .			\$86.00	\$0.00		
Multiple Dependent Claims (check if applicable).						\$0.00		
TOTAL OF ABOVE CALCULATIONS =						\$974.00	 	
Applicant claims small entity status. See 37 reduced by 1/2.	CFR 1.27. The f	fees indicated	labove	e are		\$0.00		
SUBTOTAL =						\$974.00		
Processing fee of \$130.00 for furnishing the English translation later than   months from the earliest claimed priority date (37 CFR 1.492(f)). +						\$0.00		
TOTAL NATIONAL FEE =						\$974.00		
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable).						\$0.00		
TOTAL FEES ENCLOSED =						\$974.00		
							\$	
						charged	\$ .	
a. A check in the amount of	to (	cover the abo	ve fee	s is e	nclosed.			
b. 🛮 Pleáse charge my Deposit Accou	nt No. <u>07-1</u>	392 in 1	he am	ount	of\$97	4.00 to cover t	he above fees.	
c.  The Director is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No07-1392								
d.  Fees are to be charged to a credit card. <b>WARNING:</b> Information on this form may become public. <b>Credit card</b> information should not be included on this form. Provide credit card information and authorization on PTO-2038.								
NOTE: Where an appropriate time limit und 1.137(a) or (b)) must be filed and granted to re	er 37 CFR 1.494 estore the Intern	or 1.495 ha ational App	s not b licatio	een :	met, a petitio pending statu	n to revive (37 CFF is.	t	
SEND ALL CORRESPONDENCE TO:					٨	trad		
				_	The state of the s	300		
CUSTOMER NUMBER		SIGNATURE						
23347				James P. Riek NAME				
	39,009 REGISTRATIO					NI NI IMPED		
September						2004		
				DA	ATE			

DT09 Recipe PCT/PTO Docket No. CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10) Rachael Ann ANCLIFF et al. Applicant(s): PG4784USw Serial No. Filing Date Examiner Group Art Unit To be assigned Concurrently herewith MORPHOLINYL-UREA DERIVATIVES FOR USE OF THE TREATMENT OF INFLAMMATORY Invention: **DISEASES** I hereby certify that the following correspondence: U.S. national phase application for patent under 35 USC 371 and accompanying documents (Identify type of correspondence) is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on September Marjorie J. Pfeiffer (Typed or Printed Name of Person Mailing Correspondence) (Signature of Person Mailing Correspondence EV332062795L Note: Each paper must have its own certificate of mailing.